These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 28755993)

  • 1. Breaching barriers in glioblastoma. Part I: Molecular pathways and novel treatment approaches.
    Miranda A; Blanco-Prieto M; Sousa J; Pais A; Vitorino C
    Int J Pharm; 2017 Oct; 531(1):372-388. PubMed ID: 28755993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Targets and Nanoparticulate Systems Designed for the Improved Therapeutic Intervention in Glioblastoma Multiforme.
    Akhter MH; Rizwanullah M; Ahmad J; Amin S; Ahmad MZ; Minhaj MA; Mujtaba MA; Ali J
    Drug Res (Stuttg); 2021 Mar; 71(3):122-137. PubMed ID: 33167048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breaching barriers in glioblastoma. Part II: Targeted drug delivery and lipid nanoparticles.
    Miranda A; Blanco-Prieto MJ; Sousa J; Pais A; Vitorino C
    Int J Pharm; 2017 Oct; 531(1):389-410. PubMed ID: 28801108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glioblastoma multiforme: a glance at advanced therapies based on nanotechnology.
    Rezaei V; Rabiee A; Khademi F
    J Chemother; 2020 May; 32(3):107-117. PubMed ID: 31984871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Advances on Glioblastoma Multiforme and Nano-drug Carriers: A Review.
    Liao W; Fan S; Zheng Y; Liao S; Xiong Y; Li Y; Liu J
    Curr Med Chem; 2019; 26(31):5862-5874. PubMed ID: 29768997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Monoclonal Antibodies Delivery for the Glioblastoma Treatment.
    Sousa F; Moura RP; Moreira E; Martins C; Sarmento B
    Adv Protein Chem Struct Biol; 2018; 112():61-80. PubMed ID: 29680243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.
    Okonogi N; Shirai K; Oike T; Murata K; Noda SE; Suzuki Y; Nakano T
    Anticancer Res; 2015 Mar; 35(3):1229-35. PubMed ID: 25750269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme.
    Aldoghachi AF; Aldoghachi AF; Breyne K; Ling KH; Cheah PS
    Neuroscience; 2022 May; 491():240-270. PubMed ID: 35395355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel sights on therapeutic, prognostic, and diagnostics aspects of non-coding RNAs in glioblastoma multiforme.
    Mekala JR; Adusumilli K; Chamarthy S; Angirekula HSR
    Metab Brain Dis; 2023 Aug; 38(6):1801-1829. PubMed ID: 37249862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approaches to physical stimulation of metallic nanoparticles for glioblastoma treatment.
    Pinel S; Thomas N; Boura C; Barberi-Heyob M
    Adv Drug Deliv Rev; 2019 Jan; 138():344-357. PubMed ID: 30414495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.
    Kim SS; Harford JB; Pirollo KF; Chang EH
    Biochem Biophys Res Commun; 2015 Dec; 468(3):485-9. PubMed ID: 26116770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized regulation of glioblastoma cancer stem cells based on biomedical technologies: From theory to experiment (Review).
    Bryukhovetskiy I; Ponomarenko A; Lyakhova I; Zaitsev S; Zayats Y; Korneyko M; Eliseikina M; Mischenko P; Shevchenko V; Shanker Sharma H; Sharma A; Khotimchenko Y
    Int J Mol Med; 2018 Aug; 42(2):691-702. PubMed ID: 29749540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New molecularly targeted therapies for glioblastoma multiforme.
    Polivka J; Polivka J; Rohan V; Topolcan O; Ferda J
    Anticancer Res; 2012 Jul; 32(7):2935-46. PubMed ID: 22753758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside.
    Li Y; Sharma A; Maciaczyk J; Schmidt-Wolf IGH
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Present and Future of Anti-Glioblastoma Therapies: A Deep Look into Molecular Dependencies/Features.
    Kim HJ; Kim DY
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33053763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glioblastoma multiforme: Pathogenesis and treatment.
    Alifieris C; Trafalis DT
    Pharmacol Ther; 2015 Aug; 152():63-82. PubMed ID: 25944528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disentangling the therapeutic tactics in GBM: From bench to bedside and beyond.
    Daisy Precilla S; Kuduvalli SS; Thirugnanasambandhar Sivasubramanian A
    Cell Biol Int; 2021 Jan; 45(1):18-53. PubMed ID: 33049091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel delivery methods bypassing the blood-brain and blood-tumor barriers.
    Hendricks BK; Cohen-Gadol AA; Miller JC
    Neurosurg Focus; 2015 Mar; 38(3):E10. PubMed ID: 25727219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.
    Lozada-Delgado EL; Grafals-Ruiz N; Vivas-Mejía PE
    Life Sci; 2017 Nov; 188():26-36. PubMed ID: 28864225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.